"For Agilent, Citi's catalyst watch centers on the removal of a key share overhang: the company's pending acquisition of Biocare Medical. Announced March 9, 2026, the $950 million all-cash deal adds more than 300 specialized antibodies and tissue diagnostic capabilities to Agilent's pathology portfolio, strengthening its position in a roughly $10 billion pathology market."
"On Icon, Citi analyst Patrick Donnelly cut the price target to $120 from $200, maintaining a Neutral rating after updating models across the life science tools and diagnostics group following Q4 reports. The cut reflects Icon's sharply altered risk profile after the company disclosed in February 2026 that an internal accounting investigation found potential revenue overstatement across fiscal years 2023 through 2025."
"The dual signal - selective optimism on recovery names, caution on an embattled CRO - reflects a broader reset in how Wall Street is positioning across life sciences heading into the second quarter."
Citi conducted a comprehensive review of life science tools and diagnostics coverage, establishing a 90-day upside catalyst watch on Agilent Technologies while reducing its price target on Icon PLC. The firm designated Agilent as its top tools pick, Natera as its top diagnostics pick, and Charles River Laboratories as its top contract research organization pick. For Agilent, the catalyst centers on closing its $950 million Biocare Medical acquisition, which adds specialized antibodies and tissue diagnostic capabilities to strengthen its pathology portfolio position. Icon's price target was cut significantly to $120 from $200 following an internal accounting investigation revealing potential revenue overstatement from 2023-2025, with results delayed until April 2026. This selective optimism on recovery names contrasts with caution on embattled CROs, reflecting Wall Street's broader repositioning across life sciences.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]